Gena Wang
Stock Analyst at Barclays
(3.06)
# 2,424
Out of 5,182 analysts
238
Total ratings
44.65%
Success rate
0.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gena Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintains: Overweight | $87 → $95 | $60.69 | +56.53% | 7 | Apr 6, 2026 | |
| LEGN Legend Biotech | Maintains: Overweight | $90 → $80 | $23.56 | +239.56% | 8 | Feb 4, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $81 → $50 | $24.53 | +103.83% | 7 | Nov 24, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Overweight | $38 → $33 | $9.46 | +248.84% | 3 | Nov 11, 2025 | |
| MRNA Moderna | Maintains: Equal-Weight | $31 → $25 | $47.14 | -46.97% | 11 | Nov 7, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $24 → $14 | $13.20 | +6.06% | 9 | Nov 7, 2025 | |
| SGMO Sangamo Therapeutics | Downgrades: Equal-Weight | $5 → $1 | $0.20 | +397.51% | 5 | Nov 7, 2025 | |
| PTCT PTC Therapeutics | Maintains: Equal-Weight | $46 → $68 | $70.26 | -3.22% | 17 | Nov 6, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Equal-Weight | $22 → $20 | $21.07 | -5.08% | 16 | Nov 5, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Equal-Weight | $408 → $414 | $430.14 | -3.75% | 18 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $9 | $7.45 | +20.81% | 8 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $9 | $8.86 | +1.58% | 11 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $460 → $527 | $302.11 | +74.44% | 9 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $95 | $71.78 | +32.35% | 14 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $80 | $53.30 | +50.09% | 16 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $8 | $4.00 | +100.00% | 5 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $7 → $17 | $45.43 | -62.58% | 10 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $37 | $8.69 | +325.78% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $42 → $56 | $52.06 | +7.57% | 17 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $21 | $30.56 | -31.28% | 10 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $31 | $10.28 | +201.56% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $3.06 | -1.96% | 9 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $9 | $27.94 | -67.79% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $25 | $8.87 | +181.85% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $18 | $9.08 | +98.24% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $9 | $7.54 | +19.36% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $275 | $5.36 | +5,030.60% | 1 | Jan 6, 2017 |
Cytokinetics
Apr 6, 2026
Maintains: Overweight
Price Target: $87 → $95
Current: $60.69
Upside: +56.53%
Legend Biotech
Feb 4, 2026
Maintains: Overweight
Price Target: $90 → $80
Current: $23.56
Upside: +239.56%
Ultragenyx Pharmaceutical
Nov 24, 2025
Maintains: Overweight
Price Target: $81 → $50
Current: $24.53
Upside: +103.83%
4D Molecular Therapeutics
Nov 11, 2025
Maintains: Overweight
Price Target: $38 → $33
Current: $9.46
Upside: +248.84%
Moderna
Nov 7, 2025
Maintains: Equal-Weight
Price Target: $31 → $25
Current: $47.14
Upside: -46.97%
Intellia Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $24 → $14
Current: $13.20
Upside: +6.06%
Sangamo Therapeutics
Nov 7, 2025
Downgrades: Equal-Weight
Price Target: $5 → $1
Current: $0.20
Upside: +397.51%
PTC Therapeutics
Nov 6, 2025
Maintains: Equal-Weight
Price Target: $46 → $68
Current: $70.26
Upside: -3.22%
Sarepta Therapeutics
Nov 5, 2025
Maintains: Equal-Weight
Price Target: $22 → $20
Current: $21.07
Upside: -5.08%
Vertex Pharmaceuticals
Nov 4, 2025
Maintains: Equal-Weight
Price Target: $408 → $414
Current: $430.14
Upside: -3.75%
Nov 4, 2025
Maintains: Overweight
Price Target: $10 → $9
Current: $7.45
Upside: +20.81%
Nov 4, 2025
Maintains: Equal-Weight
Price Target: $11 → $9
Current: $8.86
Upside: +1.58%
Oct 31, 2025
Maintains: Overweight
Price Target: $460 → $527
Current: $302.11
Upside: +74.44%
Oct 30, 2025
Maintains: Overweight
Price Target: $80 → $95
Current: $71.78
Upside: +32.35%
Oct 28, 2025
Maintains: Overweight
Price Target: $86 → $80
Current: $53.30
Upside: +50.09%
Oct 17, 2025
Maintains: Overweight
Price Target: $4 → $8
Current: $4.00
Upside: +100.00%
Sep 25, 2025
Upgrades: Equal-Weight
Price Target: $7 → $17
Current: $45.43
Upside: -62.58%
Aug 8, 2025
Maintains: Overweight
Price Target: $50 → $37
Current: $8.69
Upside: +325.78%
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $42 → $56
Current: $52.06
Upside: +7.57%
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $25 → $21
Current: $30.56
Upside: -31.28%
Feb 28, 2025
Maintains: Overweight
Price Target: $26 → $31
Current: $10.28
Upside: +201.56%
Dec 13, 2024
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $3.06
Upside: -1.96%
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $27.94
Upside: -67.79%
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $8.87
Upside: +181.85%
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $9.08
Upside: +98.24%
Aug 9, 2019
Maintains: Underweight
Price Target: $21 → $9
Current: $7.54
Upside: +19.36%
Jan 6, 2017
Initiates: Buy
Price Target: $275
Current: $5.36
Upside: +5,030.60%